viewBiocept Inc

Full interview: Biocept making progress using artificial intelligence and automation in its diagnostic lab

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO & SVP of Operations Tim Kennedy joined Christine Corrado at Proactive's New York studio following their attendance at the H.C. Wainwright Global Investment Conference, drumming up investor excitement around the cancer diagnostics company.

Both say investors are keen to hear about the company's progress with automating its laboratory processes, which Kennedy noted has allowed the company to slash costs going in the next few quarters and should be completed towards the end of 2019.

Quick facts: Biocept Inc

Price: 0.32 USD

Market: NASDAQ
Market Cap: $13.51 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Full interview: Biocept 'one of the first' liquid biopsy providers to detect...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the California-based company's Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid. Nall says the company has also managed to win a US patent for its liquid biopsy cancer testing...

4 days, 1 hour ago

2 min read